Commentary
Commentary
Cost-Saving Biosimilars’ Many Obstacles
Innovating new drugs is an expensive and uncertain business, typically taking 10-12 years and costing, on average, $2.55 billion to bring a new product to market. The risks are enormous, and deserve significant financial rewards; at the same time, it’s undeniable that the costs of many new, complex drugs are ...
Commentary
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Business & Economics
Loan rate-cap bill would harm consumers
The California Senate Banking Committee is scheduled to hold a hearing Wednesday (June 26) on a bill that caps consumer loan rates and threatens to sever a vital credit lifeline for many. Oddly, three commercial lenders who offer the kind of loans subject to this regulation support it. Assembly Bill ...
Charter Schools
Charter Schools Don’t Fiscally Distress Regular Public Schools
In their continuing war against charter schools, teacher unions have persistently argued that charter schools, which are mostly non-union, have a large negative financial impact on the regular public school system. New research, however, contradicts this claim. In Sacramento, the California Teachers Association is pushing a package of anti-charter-school bills, ...
Commentary
‘Medicare for All’ Is A Trap for Businesses and Employees
Some business leaders are hopping aboard the Medicare for All bandwagon. The Business Alliance for a Healthy California, for example, now has 300 businesses calling for universal healthcare. But any businessman considering getting behind Medicare for All should know the sales pitch is flawed. The architects of Medicare for All ...
Commentary
Democrats don’t understand ‘Medicare-for-all’
Next week, 20 Democratic presidential hopefuls will gather in Miami for their first debate. One issue is sure to dominate the discussion – “Medicare-for-all.” The promise of free, government-run health care has become quite popular among Democrats since Sen. Bernie Sanders, I-Vt., made it a major plank of his 2016 ...
California
If Newsom Is Right, California’s Rot Is Coming To The Rest Of America
California Democratic Gov. Gavin Newsom predicted this week that the Republican Party will “will go into the waste bin of society.” It was an interesting comment, coming only a couple of weeks after his party’s presidential candidates appeared at California’s Democratic Party convention. That convention showed why California is moving in a ...
Commentary
Medicaid expansion is a failure: Lots of spending, little benefit
Researchers from MIT and Harvard recently released a report concluding that Obamacare had a “clearly positive effect on access to and consumption of health care.” Nearly 16 million people gained coverage through Medicaid expansion while just over 11 million purchased insurance through Obamacare’s exchanges in the past year. But that ...
Commentary
We Need Reciprocity Of Drug Approvals To Address Critical Drug Shortages
By Henry I. Miller and John J. Cohrssen Published in Issues and Insights We hear a lot about rising drug prices, but largely ignored is a far more acute and worrisome problem: widespread shortages of critical medications, many of which are essential in medical practice. University of Chicago researchers last ...
Commentary
FDA must do more to protect consumers from ‘outright fraud’ of dietary supplements
By Henry I. Miller and Josh Bloom Published in Genetic Literacy Project Dietary supplements are big business. Three out of four Americans take one or more on a regular basis, and for older Americans the fraction is four out of five. One in three children also takes supplements. The estimated ...
Cost-Saving Biosimilars’ Many Obstacles
Innovating new drugs is an expensive and uncertain business, typically taking 10-12 years and costing, on average, $2.55 billion to bring a new product to market. The risks are enormous, and deserve significant financial rewards; at the same time, it’s undeniable that the costs of many new, complex drugs are ...
Flawed WHO Study Could Jeopardize Patients’ Access to Cancer Medicines
Determining whether the prices for medicines are appropriate or not is critically important, which is why studies that attempt to answer this question must stand up to scrutiny. Studies that undervalue medicines jeopardize the development of future cures, while studies that overvalue medicines justify the imposition of excessive health care ...
Loan rate-cap bill would harm consumers
The California Senate Banking Committee is scheduled to hold a hearing Wednesday (June 26) on a bill that caps consumer loan rates and threatens to sever a vital credit lifeline for many. Oddly, three commercial lenders who offer the kind of loans subject to this regulation support it. Assembly Bill ...
Charter Schools Don’t Fiscally Distress Regular Public Schools
In their continuing war against charter schools, teacher unions have persistently argued that charter schools, which are mostly non-union, have a large negative financial impact on the regular public school system. New research, however, contradicts this claim. In Sacramento, the California Teachers Association is pushing a package of anti-charter-school bills, ...
‘Medicare for All’ Is A Trap for Businesses and Employees
Some business leaders are hopping aboard the Medicare for All bandwagon. The Business Alliance for a Healthy California, for example, now has 300 businesses calling for universal healthcare. But any businessman considering getting behind Medicare for All should know the sales pitch is flawed. The architects of Medicare for All ...
Democrats don’t understand ‘Medicare-for-all’
Next week, 20 Democratic presidential hopefuls will gather in Miami for their first debate. One issue is sure to dominate the discussion – “Medicare-for-all.” The promise of free, government-run health care has become quite popular among Democrats since Sen. Bernie Sanders, I-Vt., made it a major plank of his 2016 ...
If Newsom Is Right, California’s Rot Is Coming To The Rest Of America
California Democratic Gov. Gavin Newsom predicted this week that the Republican Party will “will go into the waste bin of society.” It was an interesting comment, coming only a couple of weeks after his party’s presidential candidates appeared at California’s Democratic Party convention. That convention showed why California is moving in a ...
Medicaid expansion is a failure: Lots of spending, little benefit
Researchers from MIT and Harvard recently released a report concluding that Obamacare had a “clearly positive effect on access to and consumption of health care.” Nearly 16 million people gained coverage through Medicaid expansion while just over 11 million purchased insurance through Obamacare’s exchanges in the past year. But that ...
We Need Reciprocity Of Drug Approvals To Address Critical Drug Shortages
By Henry I. Miller and John J. Cohrssen Published in Issues and Insights We hear a lot about rising drug prices, but largely ignored is a far more acute and worrisome problem: widespread shortages of critical medications, many of which are essential in medical practice. University of Chicago researchers last ...
FDA must do more to protect consumers from ‘outright fraud’ of dietary supplements
By Henry I. Miller and Josh Bloom Published in Genetic Literacy Project Dietary supplements are big business. Three out of four Americans take one or more on a regular basis, and for older Americans the fraction is four out of five. One in three children also takes supplements. The estimated ...
